2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hydrochloride, (S)- → Timolol

HRID 1826578Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1826578
[CH3:1][C:2]([NH:5][CH2:6][C@H:7]([OH:21])[CH2:8][O:9][C:10]1[C:11]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)=[N:12][S:13][N:14]=1)([CH3:4])[CH3:3].Cl>C([O-])(=O)C>[CH3:4][C:2]([NH:5][CH2:6][C@H:7]([OH:21])[CH2:8][O:9][C:10]1[C:11]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)=[N:12][S:13][N:14]=1)([CH3:1])[CH3:3]

Komponenten

3

Edukt 1

HCID 1552082-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hydrochloride, (S)-

Produkt 1

HCID 33624Timolol

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 175AcetateLösungsmittel

Versuchsvorschrift

Timolol HCl (3-tert-butylamino-1-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol) is a beta-blocker for treatment of glaucoma. The drug is dissolved in a final concentration of 0.5% (m/v) in 20 mM acetate buffer pH 5.2. After the addition of chitosan-4-thio-butyl-amidine conjugate in a final concentration of 0.1% (m/v) and a preservative in a final concentration of 0.03% (m/v), the pH-value is readjusted to pH 5.2. Remaining oxygen is removed by bubbling the solution with nitrogen. The resulting eye drops are filled up under inert conditions in multiple unit vessels of 10 ml. The vessels are than sealed with an aluminium-foil.

Aufarbeitung

  1. customRemaining oxygen is removed
  2. customby bubbling the solution with nitrogen
  3. additionThe resulting eye drops are filled up under inert conditions in multiple unit vessels of 10 ml
  4. customthan sealed with an aluminium-foil

Quellen und Nachweise

ORD-Eintrag
ord-ac5a061bae6440cf8c1547d75a44897e
Quelldatensatz
uspto-grants-2006_05
Patentnummer
US07053068B2

Notizen zur Reaktion

Wird geladen…